Amani Therapeutics
Other Health Care company with a recent SEC Form D offering.
Other Health Care company headquartered in NEW YORK, NEW YORK. Filed SEC Form D on 20261001 for a $35.0M Regulation D offering.
Healthcare
📍 NEW YORK, NEW YORK
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Amani Therapeutics going public?
No. Amani Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Amani Therapeutics' valuation in 2026?
No confirmed valuation is on record for Amani Therapeutics. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Amani Therapeutics filed an S-1?
No public S-1 is on file for Amani Therapeutics.
How much has Amani Therapeutics raised?
Amani Therapeutics has raised $35M in total, most recently a Form D filing of $35M in 20261001.
Is Amani Therapeutics publicly traded — can you buy Amani Therapeutics stock?
No. Amani Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Amani Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Growth
Filed SEC Form D on 20261001 for $35.0M Regulation D offering
Last Round
Form D filing — $35M (20261001)
Fundraising Status
Form D filing · $35M
privateTotal raised $35M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Form D filing | $35M | 20261001 | — | — |
Talent Signal
Hiring data for Amani Therapeutics has not been collected yet — the monthly talent sweep hasn't reached this company. Check back soon.
HealthcareForm DRecently Funded
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.